From Lab to Clinic: The Clinical Translation and Engineering of Clostridium novyi- NT for Cancer Therapy

The transition of bacterial cancer therapy from a historical concept to a tangible clinical modality is exemplified by the development of Clostridium novyi-NT. This engineered, non-toxic strain has emerged as a pioneering biotherapeutic with a unique mechanism of action targeting the hostile tumor microenvironment. This review delineates the trajectory of C. novyi-NT, from its genesis via genetic engineering to its assessment in preclinical models and clinical trials. We elaborate on the strain's development, focusing on the deletion of the alpha-toxin gene and its subsequent safety profile. The discourse extends to its application in multifaceted combination strategies, particularly the Combination Bacteriolytic Therapy (COBALT) with microtubule-disrupting agents, which has demonstrated synergistic efficacy and complete tumor eradication in robust models. We further examine its capacity to subvert drug resistance by dismantling hypoxic sanctuaries and modulating key resistance mediators such as HIF-۱a and VEGF. The review also synthesizes findings from ongoing clinical trials, including the combination of C. novyi- NT with immune checkpoint inhibitors like pembrolizumab, which has yielded promising early results. Finally, we explore cutting-edge genetic engineering tools that are paving the way for next-generation, "armed" clostridial strains for safer and more potent targeted cancer therapy. The journey of C. novyi-NT validates the potential of engineered bacteria as a powerful and unique modality in the oncotherapeutic arsenal.

کلیدواژه ها:

Clostridium novyi-NT ، Bacterial Cancer Therapy ، Genetic Engineering ، COBALT ، Clinical Trials